The demand for products and services has been slashed, manufacturing disrupted and the supply chain is running out. The impact from the ongoing coronavirus outbreak in China is only starting to surface, with possible diversification of sourcing one key topic that has been thrown up for the global pharma industry.
10 days since most offices reopened and workers started slowly returning to work, many companies are still operating on uneven...








